Novartis received FDA approval for Fabhalta (iptacopan) as the first oral monotherapy for adults with PNH
On Dec. 5, 2023, Novartis announced that the U.S. Food and Drug Administration (FDA) had approved Fabhalta (iptacopan)…
paroxysmal nocturnal hemoglobinuria